Guggenheim initiated coverage of Cybin (CYBN) with a Buy rating and $35 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Inc. Reports Q3 2025 Financial Results and Strategic Progress
- Psychedelic: MindMed reports Q4 earnings results
- Psychedelic: GH Research, Compass Pathways report earnings results
- Psychedelic: Exclusive talk with biotech company Enveric Biosciences
- Cybin price target lowered to $150 from $190 at H.C. Wainwright